These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 12679199)

  • 1. Effects of nonstatin lipid drug therapy on high-density lipoprotein metabolism.
    Rader DJ
    Am J Cardiol; 2003 Apr; 91(7A):18E-23E. PubMed ID: 12679199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current Therapies Focused on High-Density Lipoproteins Associated with Cardiovascular Disease.
    Estrada-Luna D; Ortiz-Rodriguez MA; Medina-Briseño L; Carreón-Torres E; Izquierdo-Vega JA; Sharma A; Cancino-Díaz JC; Pérez-Méndez O; Belefant-Miller H; Betanzos-Cabrera G
    Molecules; 2018 Oct; 23(11):. PubMed ID: 30360466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of statins on high-density lipoproteins.
    Schaefer EJ; Asztalos BF
    Curr Atheroscler Rep; 2006 Jan; 8(1):41-9. PubMed ID: 16455013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
    Hausenloy DJ; Yellon DM
    Heart; 2008 Jun; 94(6):706-14. PubMed ID: 18480348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacologic elevation of high-density lipoproteins: recent insights on mechanism of action and atherosclerosis protection.
    Meyers CD; Kashyap ML
    Curr Opin Cardiol; 2004 Jul; 19(4):366-73. PubMed ID: 15218398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The pharmacokinetics and pharmacodynamics of agents proven to raise high-density lipoprotein cholesterol.
    Piepho RW
    Am J Cardiol; 2000 Dec; 86(12A):35L-40L. PubMed ID: 11374854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 'Trig-onometry': non-high-density lipoprotein cholesterol as a therapeutic target in dyslipidaemia.
    Jacobson TA
    Int J Clin Pract; 2011 Jan; 65(1):82-101. PubMed ID: 21105969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination therapy with statins and omega-3 fatty acids.
    Nambi V; Ballantyne CM
    Am J Cardiol; 2006 Aug; 98(4A):34i-38i. PubMed ID: 16919515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
    Hausenloy DJ; Yellon DM
    Postgrad Med J; 2008 Nov; 84(997):590-8. PubMed ID: 19103817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.
    Evans M; Roberts A; Davies S; Rees A
    Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HDL-Targeting Therapeutics: Past, Present and Future.
    Zakiev E; Feng M; Sukhorukov V; Kontush A
    Curr Pharm Des; 2017; 23(8):1207-1215. PubMed ID: 27799042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HDL-C: role as a risk modifier.
    Barter P
    Atheroscler Suppl; 2011 Nov; 12(3):267-70. PubMed ID: 22152280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study.
    Karas RH; Kashyap ML; Knopp RH; Keller LH; Bajorunas DR; Davidson MH
    Am J Cardiovasc Drugs; 2008; 8(2):69-81. PubMed ID: 18422390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-density lipoproteins: multifunctional vanguards of the cardiovascular system.
    Marcil M; O'Connell B; Krimbou L; Genest J
    Expert Rev Cardiovasc Ther; 2004 May; 2(3):417-30. PubMed ID: 15151487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors ("statins") in familial combined hyperlipidemia.
    Schonfeld G; Aguilar-Salina C; Elias N
    Am J Cardiol; 1998 Feb; 81(4A):43B-46B. PubMed ID: 9526813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-density lipoprotein particles, coronary heart disease, and niacin.
    Asztalos BF
    J Clin Lipidol; 2010; 4(5):405-10. PubMed ID: 21122684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of hypercholesterolaemia in postmenopausal women.
    Davidson MH; Maki KC; Karp SK; Ingram KA
    Drugs Aging; 2002; 19(3):169-78. PubMed ID: 12027776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological management of high triglycerides and low high-density lipoprotein cholesterol.
    Szapary PO; Rader DJ
    Curr Opin Pharmacol; 2001 Apr; 1(2):113-20. PubMed ID: 11714084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Therapeutic targets in the treatment of dyslipidemia: HDL and non-HDL cholesterol].
    Brea Hernando ÁJ
    Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():3-6. PubMed ID: 25043539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.